Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
Top Cited Papers
Open Access
- 25 October 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 119 (9), 1067-1074
- https://doi.org/10.1038/s41416-018-0310-8
Abstract
Background PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) with vaginal brachytherapy (VBT). We evaluated long-term outcomes combined with the results of pathology review and molecular analysis. Methods 427 women with HIR endometrial cancer were randomised between 2002–2006 to VBT or EBRT. Primary endpoint was vaginal recurrence (VR). Pathology review was done in 97.4%, combined with molecular analysis. Results Median follow-up was 116 months; 10-year VR was 3.4% versus 2.4% for VBT vs. EBRT (p = 0.55). Ten-year pelvic recurrence (PR) was more frequent in the VBT group (6.3% vs. 0.9%, p = 0.004), mostly combined with distant metastases (DM). Ten-year isolated PR was 2.5% vs. 0.5%, p = 0.10, and DM 10.4 vs. 8.9% (p = 0.45). Overall survival for VBT vs. EBRT was 69.5% vs. 67.6% at 10 years (p = 0.72). L1CAM and p53-mutant expression and substantial lymph-vascular space invasion were risk factors for PR and DM. EBRT reduced PR in cases with these risk factors. Conclusion Long-term results of the PORTEC-2 trial confirm VBT as standard adjuvant treatment for HIR endometrial cancer. Molecular risk assessment has the potential to guide adjuvant therapy. EBRT provided better pelvic control in patients with unfavourable risk factors.Keywords
Funding Information
- KWF Kankerbestrijding (CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719)
This publication has 35 references indexed in Scilit:
- L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter EvaluationJNCI Journal of the National Cancer Institute, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Preliminary Results of Whole Brain Radiotherapy With Concurrent Trastuzumab for Treatment of Brain Metastases in Breast Cancer PatientsInternational Journal of Radiation Oncology*Biology*Physics, 2011
- A Role for Adjuvant Radiation in Clinically Early Carcinoma of the Endometrium?International Journal of Gynecologic Cancer, 2010
- Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysisThe Lancet, 2009
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised studyThe Lancet, 2009
- Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical TrialJNCI Journal of the National Cancer Institute, 2008
- Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trialBritish Journal of Cancer, 2006
- A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group studyGynecologic Oncology, 2004
- Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinomaCancer, 2004